Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

February 8, 2024

https://www.globenewswire.com/news-release/2024/02/08/2825867/15991/en/Amicus-Therapeutics-Receives-the-2024-New-Treatment-Award-for-Pombiliti-cipaglucosidase-alfa-atga-Opfolda-miglustat-at-the-20th-Annual-WORLDSymposium.html

PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), today announced that WORLDSymposium™ has awarded Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) the 2024 New Treatment Award, which recognizes important achievements in advancing treatments for lysosomal diseases which have attained regulatory approval.

Read more at globenewswire.com

Related news for (FOLD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.